Over 30M suffer from peripheral neuropathy (PN), or nerve damage brought on from diabetes, cancer, or an autoimmune disease.
This can manifest itself in your body or limb being hit with chronic numbness, burning, throbbing or shooting pain.
While there are significant treatments that help the issues that cause PN, there hasn’t been much advancement in treating PN itself other than pain suppression or pain management.
WinSanTor is a company that is on a mission to find a treatment for peripheral neuropathy. All initial testing points to them discovering a scientific breakthrough that both prevents and reverses PN nerve damage through nerve regrowth.
The Future of WinSanTor
The $25M WinSanTor has received thus brought them all the way to the second of three phases in clinical trials. This current round of funding will be used towards wrapping up phase two and beginning phase three of their clinical trial.
What Interested Investors Need to Know
Three things that investors should take note of:
- Scientific breakthrough: WinSanTor is on the verge of creating an actual treatment for peripheral neuropathy.
- Potential for impact: 1 in 15 Americans suffer from some form of NP so the potential market for their work is massive.
- Groundbreaking model: WinSanTor’s clinical process, which has been geared towards patient impact rather than profits could provide a new model for drug companies going forward.